Medical - Distribution
Compare Stocks
5 / 10Stock Comparison
WGRX vs DBVT vs HSIC vs ALKS vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Distribution
Biotechnology
Medical - Distribution
WGRX vs DBVT vs HSIC vs ALKS vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Distribution | Biotechnology | Medical - Distribution | Biotechnology | Medical - Distribution |
| Market Cap | $8M | $1712.35T | $8.09B | $5.90B | $92.15B |
| Revenue (TTM) | $6M | $0.00 | $13.18B | $1.56B | $403.43B |
| Net Income (TTM) | $-73M | $-168M | $398M | $153M | $4.76B |
| Gross Margin | 4.1% | — | 29.1% | 65.4% | 3.6% |
| Operating Margin | -12.1% | — | 5.8% | 12.3% | 1.5% |
| Forward P/E | — | — | 13.2x | 24.8x | 16.7x |
| Total Debt | $25M | $22M | $3.69B | $70M | $7.39B |
| Cash & Equiv. | $1M | $194M | $156M | $1.12B | $5.69B |
WGRX vs DBVT vs HSIC vs ALKS vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 25 | May 26 | Return |
|---|---|---|---|
| Wellgistics Health,… (WGRX) | 100 | 3.1 | -96.9% |
| DBV Technologies S.… (DBVT) | 100 | 443.4 | +343.4% |
| Henry Schein, Inc. (HSIC) | 100 | 98.1 | -1.9% |
| Alkermes plc (ALKS) | 100 | 101.9 | +1.9% |
| McKesson Corporation (MCK) | 100 | 115.0 | +15.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WGRX vs DBVT vs HSIC vs ALKS vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, WGRX doesn't own a clear edge in any measured category.
DBVT is the #2 pick in this set and the best alternative if momentum is your priority.
- +110.4% vs WGRX's -98.0%
HSIC ranks third and is worth considering specifically for sleep-well-at-night.
- Lower volatility, beta 0.73, Low D/E 76.9%, current ratio 1.38x
- Better valuation composite
ALKS is the clearest fit if your priority is quality.
- 9.8% margin vs WGRX's -13.0%
MCK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 17 yrs, beta 0.04, yield 0.4%
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 348.1% 10Y total return vs HSIC's 5.3%
- PEG 0.43 vs HSIC's 4.20
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs DBVT's -100.0% | |
| Value | Better valuation composite | |
| Quality / Margins | 9.8% margin vs WGRX's -13.0% | |
| Stability / Safety | Beta 0.04 vs DBVT's 1.26 | |
| Dividends | 0.4% yield; 17-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +110.4% vs WGRX's -98.0% | |
| Efficiency (ROA) | 5.7% ROA vs WGRX's -138.4%, ROIC 5.4% vs -32.2% |
WGRX vs DBVT vs HSIC vs ALKS vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
WGRX vs DBVT vs HSIC vs ALKS vs MCK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MCK leads in 3 of 6 categories
ALKS leads 1 • WGRX leads 0 • DBVT leads 0 • HSIC leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK and DBVT operate at a comparable scale, with $403.4B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to WGRX's -13.0%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $6M | $0 | $13.2B | $1.6B | $403.4B |
| EBITDAEarnings before interest/tax | -$65M | -$112M | $1.1B | $212M | $6.8B |
| Net IncomeAfter-tax profit | -$73M | -$168M | $398M | $153M | $4.8B |
| Free Cash FlowCash after capex | -$7M | -$151M | $561M | $392M | $6.0B |
| Gross MarginGross profit ÷ Revenue | +4.1% | — | +29.1% | +65.4% | +3.6% |
| Operating MarginEBIT ÷ Revenue | -12.1% | — | +5.8% | +12.3% | +1.5% |
| Net MarginNet income ÷ Revenue | -13.0% | — | +3.0% | +9.8% | +1.2% |
| FCF MarginFCF ÷ Revenue | -130.5% | — | +4.3% | +25.1% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -80.9% | — | +7.7% | +28.2% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -11.8% | +91.5% | +14.9% | -4.1% | +37.0% |
Valuation Metrics
Evenly matched — DBVT and HSIC and MCK each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, HSIC trades at a 26% valuation discount to MCK's 29.2x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs HSIC's 6.84x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $8M | $1712.35T | $8.1B | $5.9B | $92.1B |
| Enterprise ValueMkt cap + debt − cash | $32M | $1712.35T | $11.6B | $4.9B | $93.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.68x | -0.76x | 21.56x | 24.76x | 29.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 13.25x | — | 16.66x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 6.84x | — | 0.75x |
| EV / EBITDAEnterprise value multiple | — | — | 10.87x | 17.25x | 18.74x |
| Price / SalesMarket cap ÷ Revenue | 0.44x | — | 0.61x | 4.00x | 0.26x |
| Price / BookPrice ÷ Book value/share | 0.68x | 0.66x | 1.79x | 3.28x | — |
| Price / FCFMarket cap ÷ FCF | — | — | 14.12x | 12.28x | 17.63x |
Profitability & Efficiency
MCK leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-11 for WGRX. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to WGRX's 3.73x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs HSIC's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -10.8% | -130.2% | +8.2% | +8.8% | +3.0% |
| ROA (TTM)Return on assets | -138.4% | -89.0% | +3.6% | +5.4% | +5.7% |
| ROICReturn on invested capital | -32.2% | — | +7.1% | +18.9% | +5.4% |
| ROCEReturn on capital employed | -73.4% | -145.7% | +9.8% | +14.2% | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 4 | 7 | 6 |
| Debt / EquityFinancial leverage | 3.73x | 0.13x | 0.77x | 0.04x | — |
| Net DebtTotal debt minus cash | $24M | -$172M | $3.5B | -$1.0B | $1.7B |
| Cash & Equiv.Liquid assets | $1M | $194M | $156M | $1.1B | $5.7B |
| Total DebtShort + long-term debt | $25M | $22M | $3.7B | $70M | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | -10.95x | -189.82x | 4.59x | 32.30x | 33.79x |
Total Returns (Dividends Reinvested)
MCK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $232 for WGRX. Over the past 12 months, DBVT leads with a +110.4% total return vs WGRX's -98.0%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs WGRX's -71.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -79.7% | +4.9% | -8.2% | +25.3% | -8.5% |
| 1-Year ReturnPast 12 months | -98.0% | +110.4% | +5.9% | +16.5% | +4.6% |
| 3-Year ReturnCumulative with dividends | -97.7% | +19.7% | -11.7% | +14.5% | +106.4% |
| 5-Year ReturnCumulative with dividends | -97.7% | -69.1% | -12.5% | +60.9% | +286.9% |
| 10-Year ReturnCumulative with dividends | -97.7% | -87.0% | +5.3% | -11.0% | +348.1% |
| CAGR (3Y)Annualised 3-year return | -71.5% | +6.2% | -4.0% | +4.6% | +27.3% |
Risk & Volatility
Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs WGRX's 1.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.99x | 1.26x | 0.72x | 1.00x | -0.02x |
| 52-Week HighHighest price in past year | $7.04 | $26.18 | $89.29 | $36.60 | $999.00 |
| 52-Week LowLowest price in past year | $0.08 | $7.53 | $61.95 | $25.17 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +1.3% | +76.3% | +79.0% | +96.7% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 31.2 | 48.1 | 39.1 | 60.2 | 16.2 |
| Avg Volume (50D)Average daily shares traded | 13.8M | 252K | 1.2M | 2.3M | 757K |
Analyst Outlook
MCK leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: DBVT as "Buy", HSIC as "Hold", ALKS as "Buy", MCK as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 21.2% for HSIC (target: $85). MCK is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | — | $46.33 | $85.43 | $46.00 | $994.86 |
| # AnalystsCovering analysts | — | 15 | 32 | 28 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 0 | 1 | 0 | 17 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +10.5% | +0.5% | +3.4% |
MCK leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). ALKS leads in 1 (Income & Cash Flow). 2 tied.
WGRX vs DBVT vs HSIC vs ALKS vs MCK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is WGRX or DBVT or HSIC or ALKS or MCK a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — WGRX or DBVT or HSIC or ALKS or MCK?
On trailing P/E, Henry Schein, Inc.
(HSIC) is the cheapest at 21. 6x versus McKesson Corporation at 29. 2x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 43x versus Henry Schein, Inc. 's 4. 20x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — WGRX or DBVT or HSIC or ALKS or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -97. 7% for Wellgistics Health, Inc. (WGRX). Over 10 years, the gap is even starker: MCK returned +339. 0% versus WGRX's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — WGRX or DBVT or HSIC or ALKS or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.
02β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately -7786% more volatile than MCK relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 4% for Wellgistics Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — WGRX or DBVT or HSIC or ALKS or MCK?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — WGRX or DBVT or HSIC or ALKS or MCK?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -37. 8% for Wellgistics Health, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -33. 9% for WGRX. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is WGRX or DBVT or HSIC or ALKS or MCK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 43x versus Henry Schein, Inc. 's 4. 20x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 2x forward P/E versus 16. 7x for McKesson Corporation — 3. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — WGRX or DBVT or HSIC or ALKS or MCK?
In this comparison, MCK (0.
4% yield) pays a dividend. WGRX, DBVT, HSIC, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is WGRX or DBVT or HSIC or ALKS or MCK better for a retirement portfolio?
For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
02), +339. 0% 10Y return). Both have compounded well over 10 years (MCK: +339. 0%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between WGRX and DBVT and HSIC and ALKS and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: WGRX is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; HSIC is a small-cap quality compounder stock; ALKS is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.